TITLE

Characteristics of fine vascular network pattern associated with recurrence of polypoidal choroidal vasculopathy

AUTHOR(S)
Oishi, A.; Mandai, M.; Kimakura, M.; Nishida, A.; Kurimoto, Y.
PUB. DATE
August 2011
SOURCE
Eye;Aug2011, Vol. 25 Issue 8, p1020
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
ObjectiveTo characterize an irregular capillary-like structure in the vascular network of eyes with polypoidal choroidal vasculopathy (PCV), and to determine whether its presence after photodynamic therapy (PDT) can be used to predict the clinical course of PCV.MethodsWe reviewed the clinical records of 29 eyes of 29 patients with PCV, who underwent PDT and confocal retinal angiographic examinations every 3 months. The images obtained before the PDT were compared with those after the PDT. The correlations between angiography findings and recurrences were evaluated.ResultsAn area of fine, densely packed capillary-like vessels, named the fine vascular network, was identified within the polypoidal vascular network in 25 of 29 cases at the initial examination. The fine vascular network regressed in 23 cases (92%) after the first PDT. Thereafter, the fine vascular network remained or enlarged in 19 eyes, and 17 (84.5%) of these eyes had a recurrence of the polypoidal lesions or had exudative changes. In contrast, recurrences were found in only 2 of 10 (20%) eyes, whose fine network had regressed without a subsequent enlargement (P<0.001 compared with the former group).ConclusionsA fine irregular vascular network is present in the majority of eyes with PCV before PDT. Its presence or expansion after PDT was significantly associated with a recurrence of PCV. Thus, we recommend that this network be monitored after treatment to determine whether a polypoidal vascular network will recur.
ACCESSION #
64135013

 

Related Articles

  • Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results. Grewal, D S; Gill, M K; Sarezky, D; Lyon, A T; Mirza, R G // Eye;Jul2014, Vol. 28 Issue 7, p895 

    PurposeTo describe the efficacy of intravitreal aflibercept on 12-month visual and anatomical outcomes in patients with neovascular age-related macular degeneration (AMD) recalcitrant to prior monthly intravitreal bevacizumab or ranibizumab.MethodsNon-comparative case series of 21 eyes of 21 AMD...

  • Breakthrough studies revive discussion of anti-VEGF treatment regimens for AMD.  // Ocular Surgery News Europe;Feb2012, Vol. 23 Issue 2, p1 

    The article tackles the retrospective observational study LUMIERE which examined the current practices of ranibizumab treatment in France which were presented at the 2011 Association for Research in Vision and Ophthalmology meeting. The study has reportedly revived discussion of anti-vascular...

  • Intravitreal bevacizumab injection for peripheral exudative hemorrhagic chorioretinopathy. Alforja, María; Sabater, Noelia; Giralt, Joan; Adán, Alfredo; Pelegrín, Laura; Casaroli-Marano, Ricardo // Japanese Journal of Ophthalmology;Jul2011, Vol. 55 Issue 4, p425 

    A case study is presented of a woman who was referred for suspicion of a choroidal malignant melanoma oculus dexter (OD) with decreasing visual acuity. A diagnosis of peripheral exudative hemorrhagic chorioretinopathy (PECHR) was given. The use of an intravitreal injection of bevacizumab was...

  • Eylea Snares Second Approval. Shechtman, Diana L.; Karpecki, Paul M. // Review of Optometry;12/15/2012, Vol. 149 Issue 12, p67 

    The article discusses the drug approval of the anti-vascular endothelial growth factor (VEGF) agent, Eylea for the treatment of wet age related macular degeneration (AMD) and macular edema secondary to retinal vein occlusion. It further compares the drug with another ant wet AMD drug, Lucentis....

  • Researcher: Data inconclusive on as-needed anti-VEGF therapy.  // Ocular Surgery News;11/25/2009, Vol. 27 Issue 22, p21 

    The article reveals the paucity of evidence supporting the idea that as-needed anti-vascular endothelial growth factor (VEGF) therapy is either superior or inferior to monthly dosing in the treatment age-related macular degeneration, according to ophthalmologist Carl D. Regillo. Dosing...

  • Saving sight. Curtis, Keryn // Australian Ageing Agenda;May/Jun2012, p74 

    The article provides information regarding the age-related macular degeneration (AMD), and its treatment. It states that AMD causes visual impairment for those more than 50 years old in developed countries. It says that injections of anti-vascular endothelial growth factor (VEGF) agents are...

  • Anti-VEGF Works Even in Presence of Macular Traction.  // Review of Ophthalmology;Dec2012, Vol. 19 Issue 12, p3 

    The article focuses on a 2012 study by Mayo Clinic showing effectiveness of anti-vascular endothelial growth factor (VEGF) injections for treatment of wet macular degeneration even in patients with macular traction disorders.

  • Anti-PDGF found safe. Krader, Cheryl Guttman; Ho, Allen C. // Ophthalmology Times;4/15/2010, Vol. 35 Issue 8, p44 

    The article discusses the result of the phase I clinical study of Ophthotec's E10030 anti-platelet-derived growth factor aptamer for the treatment of neovascular age-related macular degeneration (AMD). It was found that E10030 is well-tolerated when used with anti-vascular endothelial growth...

  • Ranibizumab and the eye. Noble, Jason; Chaudhary, Varun // CMAJ: Canadian Medical Association Journal;4/19/2011, Vol. 183 Issue 7, p822 

    The article offers information on the use of the VEGF-A inhibitor ranibizumab as treatment for wet age-related macular degeneration. It states that several large randomized controlled trials have been conducted to examine the efficacy and safety of ranibizumab. It also says that systemic adverse...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics